Cancer treatment has advanced significantly over the past decade, and immunotherapy has become one of the most effective options for many patients. Among these innovative medicines, Nivolumab has gained global recognition for treating several types of cancer. In Pakistan, many patients and caregivers search for accurate information regarding the price, availability, and benefits of the Nivolumab 100 mg injection before starting treatment.
Nivolumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells more effectively. It belongs to a class of medicines known as PD-1 inhibitors. Doctors commonly prescribe it for conditions such as lung cancer, melanoma, kidney cancer, liver cancer, Hodgkin lymphoma, and several other advanced cancers.
Unlike traditional chemotherapy, immunotherapy targets the immune system instead of directly attacking healthy and cancerous cells alike. Because of this, many patients experience improved treatment outcomes and, in some cases, fewer side effects compared to conventional therapies.
The price of Nivolumab 100 mg injection in Pakistan generally ranges between PKR 85,000 and PKR 150,000 per vial. The cost may vary depending on several factors, including:
In major cities like Karachi, Lahore, and Islamabad, the medicine is usually available at specialized oncology pharmacies and cancer hospitals. Some hospitals may also offer package pricing that includes administration charges and consultation fees.
Most immunotherapy drugs used in Pakistan are imported from international pharmaceutical manufacturers. Due to customs duties and shipping expenses, imported cancer medicines often carry a high price tag.
Different hospitals and pharmacies apply varying profit margins. Large oncology centers sometimes provide more competitive pricing compared to smaller suppliers.
The total treatment cost depends on the dosage prescribed by the oncologist. Some patients may require repeated doses every two to four weeks, which can significantly increase overall expenses.